Diagnosis of coeliac disease using a gliadin epitope

Details Diagnosis of coeliac disease using a gliadin epitope Diagnosis of coeliac disease using a gliadin epitope

2006-12-05

2006-12-05

Saunders, David (Department: 1644)

Drug, bio-affecting and body treating compositions

In vivo diagnosis or in vivo testing

Diagnostic or test agent produces visible change on skin

C424S185100, C435S007240, C435S007940, C435S007950, C435S975000, C514S002600, C514S012200, C514S013800, C514S014800, C514S015800, C514S016700, C530S324000, C530S325000, C530S326000, C530S327000, C530S328000, C530S329000, C530S372000, C530S374000, C530S402000

Reexamination Certificate

active

07144569

ABSTRACT:
A method of diagnosing coeliac disease, or susceptibility to coeliac disease, in an individual comprising: (a) contacting a sample from the host with an agent selected from (i) the epitope comprising sequence which is: SEQ ID NO: 1 or 2, or an equivalent sequence from a naturally occurring homologue of the gliadin represented by SEQ ID NO: 3, (ii) an epitope comprising sequence comprising: SEQ ID NO: 1, or an equivalent sequence from a naturally occurring homologue of the gliadin represented by SEQ ID NO: 3, which epitope is an isolated oligopeptide derived from a gliadin protein, (ii) an analogue of (i) or (ii) which is capable of being recognised by a T cell receptor that recognises (i) or (ii), which in the case of a peptide analogue is not more than 50 amino acids in length, or (iv) a product comprising two or more agents as defined in (i), (ii) or (iii), and (b) determining in vitro whether T cells in the sample recognises the agent; recognition by the T cells indicating that the individual has, or is susceptible to, coeliac disease. Therapeutic compositions which comprise the epitope and gliadin proteins which do not cause coeliac disease are also provided.

REFERENCES:
patent: 4459355 (1984-07-01), Cello et al.
patent: 4536475 (1985-08-01), Anderson
patent: 4945050 (1990-07-01), Sanford et al.
patent: 5036006 (1991-07-01), Sanford et al.
patent: 5100792 (1992-03-01), Sanford et al.
patent: 5177010 (1993-01-01), Goldman et al.
patent: 5179022 (1993-01-01), Sanford et al.
patent: 5187073 (1993-02-01), Goldman et al.
patent: 5204253 (1993-04-01), Sanford et al.
patent: 5371014 (1994-12-01), Matsuyama et al.
patent: 5405765 (1995-04-01), Vasil et al.
patent: 5464763 (1995-11-01), Schilperoort et al.
patent: 5478744 (1995-12-01), Sanford et al.
patent: 5484956 (1996-01-01), Lundquist et al.
patent: 5489520 (1996-02-01), Adams et al.
patent: 5508468 (1996-04-01), Lundquist et al.
patent: 5510318 (1996-04-01), Patel et al.
patent: 5538877 (1996-07-01), Lundquist et al.
patent: 5554798 (1996-09-01), Lundquist et al.
patent: 5565346 (1996-10-01), Facciotti
patent: 0242236 (1987-10-01), None
patent: 0255378 (1988-02-01), None
patent: 0293358 (1988-11-01), None
patent: 442174 (1991-08-01), None
patent: 486233 (1992-05-01), None
patent: 486234 (1992-05-01), None
patent: 604662 (1994-07-01), None
patent: 672752 (1995-09-01), None
patent: 0693119 (1997-01-01), None
patent: 0 905 518 (1999-03-01), None
patent: 539563 (2001-10-01), None
patent: WO 91/02071 (1991-02-01), None
patent: WO 92/000377 (1992-01-01), None
patent: WO 92/17580 (1992-10-01), None
patent: WO 92/20809 (1992-11-01), None
patent: WO 94/13863 (1994-06-01), None
patent: WO 95/06128 (1995-03-01), None
patent: WO 98/23960 (1998-06-01), None
patent: WO 98/45460 (1998-10-01), None
patent: WO 98/45461 (1998-10-01), None
patent: WO 99/20775 (1999-04-01), None
patent: WO 02/083722 (2002-10-01), None
patent: WO 03/066079 (2003-08-01), None
patent: WO 03/096984 (2003-11-01), None
patent: WO 03/104273 (2003-12-01), None
Godkin, A.S. et al. Identification of a Coeliac Disease-Specific T Cell Epitope from A-Gliadin;Gut; vol. 44, suppl. p. A72, Apr. 1999.
Arentz-Hansen, Helene; The Intestinal T Cell Response to α-Gliadin in Adult Celiac Disease is Focused on a Single Deamidated Glutamine Targeted by Tissue Transglutaminase;J. Exp. Med.vol. 191, No. 4; Feb. 2000 603-612.
Anderson, Robert et al.;in vivoantigen challenge in celiac disease identifies a single transglutaminase-modified peptide as the dominant A-gliadin T-cell epitope;Nature Medicinevol. 6, No. 3, Mar. 2000; 337-342.
Uhlig, H. et al., Role of Tissue Transglutaminase in Gliadin Binding to Reticular Extracellular Matrix and Relation to Coeliac Disease Autoantibodies;Autoimmunity, vol. 28, pp. 185-195.
Database Swissprot Online! ID: GDA4-Wheat ACC:P04724, Aug. 13, 1987 (Abstract).
Okita, T. et al., Evolution and Heterogeneity of the α-1β-type and γ-type Gliadin DNA Sequences;The Journal of Biological Chemistry; vol. 260, No. 13, Jul. 5, 1985; pp. 8203-8213.
Troncone, R. et al. Cytokines produced by Gliadin-Specific T Cell Clones from the Coeliac Mucosa;Gastroenterology, vol. 110, No. 4, p. A103, Apr. 1996.
Van De Wal, Y et al., Small intestinal T cells of celiac disease patients recognize a natural pepsin fragment of gliadin;Proc. Natl. Acad. Sci.vol. 95, pp. 10050-10054, Aug. 1998; Immunology.
O'Keeffe, J. et al. T cell proliferation, MHC class II restriction and cytokine products of gliadin-stimulated peripheral blood mononuclear cells (PBMC);Clin Exp. Immunol; 1999; 117:269-276.
Altschul “A protein alignment scoring system sensitive at all evolutionary distances,”J Mol Evol(1993) 36(3):290-300.
Altschul et al., “Basic local alignment search tool,”J Mol Biol(1990) 215(3):403-410.
Bunce et al., “Phototyping:comprehensive DNA typing for HLA-A, B, C, DRB1, DRB3, DRB4, DRB5 & DQB1 by PCR with 144 primer mixes utilizing sequence-specific primers (PCR-SSP),”Tissue Antigens(1995) 46(5):355-367.
Dalta et al., “Plant promoters for transgene expression,”Biotechnology Ann Rev(1997) 3:269-296.
Devereux et al., “A comprehensive set of sequence analysis programs for the VAX,”Nucleic Acids Research(1984) 12(1 Pt 1):387-395.
Greenberg et al., “Transglutaminases: multifunctional cross-linking enzymes that stabilize tissues,”FASEB(1991) 5(15):3071-3077.
Henikoff “Amino acid substitution matrices from protein blocks,”Proc. Natl. Acad Sci USA(1992) 89(22):10915-10919.
Karlin et al., “Applications and statistics for multiple high-scoring segments in molecular sequences,”Proc Natl Acad USA(1993) 90(12):5873-5887.
Kohler et al., “Continuous cultures of fused cells secreting antibody of predefined specificity,”Nature(1975) 256(5517):495-497.
Kricka “Prospects for chemiluminescent and bioluminescent immunoassay and nucleic acid assays in food testing and the pharmaceutical industry,”J Biolumin Chemilumin(1998) 13(4):189-193.
Lalvani et al., “Rapid effector function in CD8+ memory T cells,”J Exp Med(1997) 186(6):859-865.
Mantzaris et al., “In vivo toxicity of a synthetic dodecapeptide from A gliadin in patients with coeliac disease,”Gastroenterol.(1991) 26(4):392-398.
Maiuri et al., “In vitro activities of A-gliadin-related synthetic peptides: damaging effect on the atrophic coeliac mucosa and activation of mucosal immune response in the treated coeliac mucosa,”Scand J Gastroenterol.(1996) 31(3):247-253.
Molberg et al., “Tissue transglutaminase selectively modifies gliadin peptides that are recognized by gut-derived T cells in celiac disease,”Nature Med(1998) 4(6):713-717.
Mullighan et al., “High-resolution HLA-DQB1 typing using the polymerase chain reaction and sequence-specific primers,”Tissue Antigens(1997) 50(6):688-692.
Olerup et al., “HLA-DQB1 and -DQA1 typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours,”Tissue Antigens(1993) 41(3):119-137.
Ota et al., “T-cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis,”Nature(1990) 346(6280):183-187.
Quarsten et al., “HLA binding and T cell recognition of a tissue transglutaminase-modified gliadin epitope,”Eur J Immunol(1999) 29(8):2506-2514.
Thurau et al., “Oral tolerance in a murine model of relapsing experimental autoimmune uveoretinitis (EAU): induction of protective tolerance in primed animals,”Clin Exp Immunol(1997) 109(2):370-376.
Vasil et al., “Herbicide Resistant Fertile Transgenic Wheat Plants Obtained by Microprojectile Bombardment of Regenerable Embryogenic Callus ,”Biotechnology(1992) 10:667-674.
Weiner et al., “Oral tolerance: cytokine milieu in the gut and modulation of tolerance by cytokines,”Res Immunol(1997) 148(8-9):528-533.
Yoshida et al., “The oral administration of low-dose antigen induces activation followed by tolerization, while high-dose a

Affiliated with

Also associated with

Rating

Diagnosis of coeliac disease using a gliadin epitope does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Diagnosis of coeliac disease using a gliadin epitope, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Diagnosis of coeliac disease using a gliadin epitope will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3669494